Analysts' Top 5 Price Targets of September 2, 2025
Reading Time: 4 minutes
Cytokinetics [US23282W6057] Citigroup reaffirms Buy rating and raises the price target from $77 to $84 (80% upside potential) Cytokinetics presented the primary results of the MAPLE-HCM study at the Congress of the European Society of Cardiology . The MAPLE-HCM study is a randomized, double-blind, active-controlled Phase 3 study comparing Aficamten with Metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy ( oHCM ). The results show that Aficamten significantly improves physical performance and is superior...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
